Gapping up
In reaction to strong earnings/guidance: SIMO +4.5%, HABT +2.8%, PLAY +1.8%, RAD +1.5%, MIND +1.3%, GPN +1.1%, RPM +1%, .
M&A news: ZEP +17.8% (announces a definitive agreement to be acquired by New Mountain Capital for $20.05/share in cash in transaction valued at ~$692 mln ), AGEN +1.2% (announces the acquisition of key antibody assets of Celexion), .
Select China/Macau related names showing strength: ZNH +9.2%, SHI +6.9%, CHL +6.6%, LFC +5.9%, EJ +5.8%, CHA +4.9%, WBAI +4%, LVS +1.8%, MGM +1.8%, HSBC +1.1%
Other news: EYES +18.1% (announces first successful implant of Model of Orion I visual cortical prosthesis), OPTT +13.6% (to proceed to the next phase of U.S. DoE Power Take-Off Technology Contract), PSTR +10.6% (cont strength), RGLS +9.7% (announced the selection of RG-125 for the treatment of Non Alcoholic Steatohepatitis in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca (AZN) under the companies' strategic alliance), PHMD +8.2% (still checking), ONVO +4.6% (cont strength), INO +4.6% (selected to receive a grant from the Defense Advanced Research Projects Agency to lead a collaborative team to develop multiple treatment and prevention approaches against Ebola), BP +3.8% (in sympathy with RDS.A/BG Grp merger), NSR +3.6% (co and North American Portability Management entered into an amendment to the regional contracts, pursuant to which the Company serves as the national Local Number Portability Administrator), TSLA +3.1% (will upgrade base level Model S 60 to dual motor 70D ), TSLA +3% (confirms introduction of 250 mile range AWD Model S 70D on its blog), LODE+3% (announces high-grade intercepts from updated drilling in Lucerne), HLT +2.8% (mention in Daily Mail detailing news that China investors are looking at hotel assets), YY +2.4% (modest rebound following yday's decline), PTLA +2.1% (announces new topline data from Phase 3 ANNEXA-A Trial ), ADXS +2% (Advaxis and Merck (MRK) announce that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA), ELLI +1.7% (announced that Independent Bank has chosen Ellie Mae's Encompass all-in-one mortgage management solution as its platform for originating mortgages), ARMH +1.6% (still checking), CPHD +1.5% (announced appointment of Ilan Daskal to EVP and CFO, effective April 9, 2015), TWTR +1.4% (cont strength), AES +1.4% (announces that its AES 3C Maritza East I (Maritza) subsidiary has signed a Heads of Terms Agreement with NEK, the state-owned wholesale power company), MRK +1.1% (announced that its Chronic Hepatitis C therapy Grazoprevir/Elbasvir has been granted FDA breakthrough therapy designation)
Analyst comments: WMAR +7.5% (upgraded to Buy from Neutral at B. Riley & Co), WRES +7.5% (initiated with a Buy at Noble Financial), MPO +4.9% (initiated with a Buy at Noble Financial; tgt $2.65), XRX +2.6% (upgraded to Buy from Neutral at Citigroup), BDSI +2.2% (initiated with a Buy at Cantor Fitzgerald), DG +1.9% (target raised to $85 from $80 at Deutsche Bank), WPX+1.8% (initiated with a Buy at KLR Group), JBL +1.5% (upgraded to Outperform from Mkt Perform at Raymond James), ZEN +1.3% (initiated with a Buy at BofA/Merrill), ICPT +1.2% (added to Short-Term Buy List at Deutsche Bank), ETE +1.1% (initiated with a Conviction Buy at Goldman)
In reaction to strong earnings/guidance: SIMO +4.5%, HABT +2.8%, PLAY +1.8%, RAD +1.5%, MIND +1.3%, GPN +1.1%, RPM +1%, .
M&A news: ZEP +17.8% (announces a definitive agreement to be acquired by New Mountain Capital for $20.05/share in cash in transaction valued at ~$692 mln ), AGEN +1.2% (announces the acquisition of key antibody assets of Celexion), .
Select China/Macau related names showing strength: ZNH +9.2%, SHI +6.9%, CHL +6.6%, LFC +5.9%, EJ +5.8%, CHA +4.9%, WBAI +4%, LVS +1.8%, MGM +1.8%, HSBC +1.1%
Other news: EYES +18.1% (announces first successful implant of Model of Orion I visual cortical prosthesis), OPTT +13.6% (to proceed to the next phase of U.S. DoE Power Take-Off Technology Contract), PSTR +10.6% (cont strength), RGLS +9.7% (announced the selection of RG-125 for the treatment of Non Alcoholic Steatohepatitis in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca (AZN) under the companies' strategic alliance), PHMD +8.2% (still checking), ONVO +4.6% (cont strength), INO +4.6% (selected to receive a grant from the Defense Advanced Research Projects Agency to lead a collaborative team to develop multiple treatment and prevention approaches against Ebola), BP +3.8% (in sympathy with RDS.A/BG Grp merger), NSR +3.6% (co and North American Portability Management entered into an amendment to the regional contracts, pursuant to which the Company serves as the national Local Number Portability Administrator), TSLA +3.1% (will upgrade base level Model S 60 to dual motor 70D ), TSLA +3% (confirms introduction of 250 mile range AWD Model S 70D on its blog), LODE+3% (announces high-grade intercepts from updated drilling in Lucerne), HLT +2.8% (mention in Daily Mail detailing news that China investors are looking at hotel assets), YY +2.4% (modest rebound following yday's decline), PTLA +2.1% (announces new topline data from Phase 3 ANNEXA-A Trial ), ADXS +2% (Advaxis and Merck (MRK) announce that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA), ELLI +1.7% (announced that Independent Bank has chosen Ellie Mae's Encompass all-in-one mortgage management solution as its platform for originating mortgages), ARMH +1.6% (still checking), CPHD +1.5% (announced appointment of Ilan Daskal to EVP and CFO, effective April 9, 2015), TWTR +1.4% (cont strength), AES +1.4% (announces that its AES 3C Maritza East I (Maritza) subsidiary has signed a Heads of Terms Agreement with NEK, the state-owned wholesale power company), MRK +1.1% (announced that its Chronic Hepatitis C therapy Grazoprevir/Elbasvir has been granted FDA breakthrough therapy designation)
Analyst comments: WMAR +7.5% (upgraded to Buy from Neutral at B. Riley & Co), WRES +7.5% (initiated with a Buy at Noble Financial), MPO +4.9% (initiated with a Buy at Noble Financial; tgt $2.65), XRX +2.6% (upgraded to Buy from Neutral at Citigroup), BDSI +2.2% (initiated with a Buy at Cantor Fitzgerald), DG +1.9% (target raised to $85 from $80 at Deutsche Bank), WPX+1.8% (initiated with a Buy at KLR Group), JBL +1.5% (upgraded to Outperform from Mkt Perform at Raymond James), ZEN +1.3% (initiated with a Buy at BofA/Merrill), ICPT +1.2% (added to Short-Term Buy List at Deutsche Bank), ETE +1.1% (initiated with a Conviction Buy at Goldman)